CORRECTION: OncoCyte Q2 Adj. EPS $(0.59) Beats $(0.87) Estimate, Sales $463.00K Beat $360.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
OncoCyte (NASDAQ:OCX) reported Q2 losses of $(0.59) per share, beating the analyst consensus estimate of $(0.87) by 32.18 percent. This is a 490 percent decrease over losses from the same period last year. The company also reported quarterly sales of $463.00 thousand, beating the analyst consensus estimate of $360.00 thousand by 28.61 percent, but this is a 77.60 percent decrease over sales from the same period last year.
August 10, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
OncoCyte's Q2 results beat analyst estimates, but represent significant decreases from the same period last year. This mixed performance may lead to uncertain short-term price movements.
While OncoCyte beat analyst estimates for Q2, the significant decreases in both earnings and sales compared to the same period last year may cause investor uncertainty, potentially leading to neutral short-term price movements.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100